OMER News and Press, Omeros Corporation From 12/17/21

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

Omeros' 2021 was a year to forget with the stock dropping during the year all the way from >$23 to below $6.00. Omeros' 2022 gives it a shot to redux its narsoplimab in treatment of HSCT-TMA. Omeros' 2022 will also be the year to provide new clarity on OMIDRIA's role in light o...

CF Acquisition (NASDAQ:CFVIU) +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition (NASDAQ:DWAC) +23% on deal to take conservative video platform Rumble public Omeros (NASDAQ:OMER) +18% to sell OMID...

Omeros Corporation (NASDAQ:OMER) has added ~14.1% in the pre-market after announcing a definitive agreement to sell its OMIDRIA franchise to Rayner Surgical Group Limited for a total consideration of over $1B. The transaction includes $125M of upfront payment in addition to $200M in...

-- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-3 Inhibitors – -- Conference call today at 8:30 a.m. ET, 5:30 a.m. PT -- $125 million upfront payment and $200 million on achieveme...

MSCI will be including total 112 companies  including  Zomedica (NYSE:ZOM), Clovis Oncology (NASDAQ:CLOV), 22nd Century (NASDAQ:XXII), Omeros (NASDAQ:OMER) and Verastem (NASDAQ:VSTM) in its MSCI US Micro Cap Index as a part of Semi-Annual Index Review. MSCI excluded a...

During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...

Omeros Corporation (OMER) Q3 2021 Earnings Conference Call November 09, 2021 04:30 PM ET Company Participants Jennifer Williams - IR Greg Demopulos - Chairman and CEO Nadia Dac - CCO Mike Jacobsen - CAO Cathy Melfi - CRO Steve Whitaker - Chief Clinical Officer Conference Call Participants Col...

Omeros (NASDAQ:OMER): Q3 Non-GAAP EPS of -$0.46 beats by $0.01; GAAP EPS of -$0.36 beats by $0.12. Revenue of $30M (+14.9% Y/Y) beats by $2.04M. Press Release At September 30, 2021, Omeros had cash, cash equivalents and short-term investments available for operations of $50.4 million. For f...

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicat...